Healome Therapeutics
Edit

Healome Therapeutics

https://www.healometx.com/
Last activity: 11.07.2026
Active
Categories: BiotechDrugDeliveryHealthcareMedTechOphthalmology
Healome Therapeutics is a Birmingham (UK) based healthcare company developing treatments for restoring function in diseased and damaged tissues, with a current focus on ocular surface diseases. We engineer and locally deliver 'pro-healing' micro-environments to tackle some of the most notoriously challenging conditions known to have biological, chemical and physical drivers or pose significant drug delivery and retention challenges. ​ Our current therapies in the ocular surface disease area behave like a clear bandage you apply and forget about like a normal eye drop. Our mission in eye care is to drive big advancements in how eye conditions with a disproportionately huge impact on quality of life are treated in the clinic and managed by patients within their daily lives. We aim to create products offering more effective and longer lasting relief, that address drivers of the condition, and that are practical to use by patients and clinicians. In doing so, we will support healthcare systems to address future eye health challenges sustainably and to empower people to lead healthier and more independent lives. Twitter: https://twitter.com/healome_tx | @healome_tx
Followers
192
Mentions
4
Location: United Kingdom
Employees: 1-10
Total raised: $2.88M
Founded date: 2021

Investors 1

DateNameWebsite
28.03.2023Startup Fu...sfccapital...

Funding Rounds 2

DateSeriesAmountInvestors
07.07.2026Seed$2.67MStartup Fu...
20.10.2021Pre-Seed$206.9K-

Mentions in press and media 4

DateTitleDescription
11.07.2026Healome Therapeutics Secures £2M to Revolutionize Eye Care with Advanced Matrix TechnologyHealome Therapeutics, a UK spinout, secured £2M seed funding. Its proprietary eye-drop matrix technology promises to transform ocular surface disease treatment. This innovation delivers sustained drug action, improving retention, lubricatio...
07.07.2026Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface DiseasesBIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million ove...
07.07.2026Healome Therapeutics Closes £2M Seed FundingHealome Therapeutics, a University of Birmingham (UK) spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, closed a GBP£2m seed financing round. The round was led by Empirical Ventures, with participation...
-Healome Therapeutics“Healome Therapeutics develops novel treatments for restoring function in diseased and damaged tissues, with a current focus on ocular surface diseases. ”

Reviews 0

Sign up to leave a review

Sign up Log In